Induced pluripotent stem cells (IPS cells), generated by transcription factor-dependent nuclear reprogramming of differentiated somatic cells, are pluripotent stem cell lines that can be propagated indefinitely in culture and maintain the potential to differentiate into any cell type in the body. As iPS cells retain the same genetic make-up as the somatic cell targeted for reprogramming, these cells hold tremendous promise for uncovering novel genetic and biochemical factors that underiie diseases with complex and pooriy understood genetic influences, such as diabetes. The DRC iPS Core will establish and maintain a centralized facility for the reliable and consistent generation and propagation of reprogrammed IPS cells for use in cutting-edge research into the molecular and cellular pathologies underiying diabetes and its complications. The Core will enhance the scientific productivity of DRC projects in multiple ways: (1) By standardizing medical assessments and data collection from human subjects, as well as cell isolation protocols and reagents, the Core will allow direct comparison of data across projects and remove variability resulting from potential technical or biological differences in patient populations or cell handling. (2) As IPS cell production and propagation can be technically challenging, the Core will ensure reproducibility and comparability of results, by enforcing rigorous standards of quality control. (3) The Core will provide advanced training for investigators desiring to introduce IPS technologies into their own laboratories, increasing the currently small number of laboratories in the Boston area skilled in the isolation and culture of IPS cells. (4) The Core will provide expert advice on experimental design, regulatory documentation and interpretation of results, based on the extensive expertise of the Core Directors and Staff. (5) As the Core will be utilized by multiple labs, it will provide a venue for scientific interaction, fostering greater exchange of information among DRC Investigators and promoting productive collaborations with other Boston-based research groups. (6) The Core will help to develop new technologies that support center activities, including most notably the optimization of methods for deriving iPS cells from people with diabetes and the integration of new reprogramming technologies, including integration-free IPS generation and generation ofiPS cells from peripheral blood samples, as these become robust and available. These activities will benefit DRC Investigators and significantly accelerate advances in diabetes research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK036836-28
Application #
8725127
Study Section
Special Emphasis Panel (ZDK1-GRB-S)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
28
Fiscal Year
2014
Total Cost
$182,281
Indirect Cost
$62,950
Name
Joslin Diabetes Center
Department
Type
DUNS #
071723084
City
Boston
State
MA
Country
United States
Zip Code
02215
Ussar, Siegfried; Haering, Max-Felix; Fujisaka, Shiho et al. (2017) Regulation of Glucose Uptake and Enteroendocrine Function by the Intestinal Epithelial Insulin Receptor. Diabetes 66:886-896
Harrington, Kara R; Boyle, Claire T; Miller, Kellee M et al. (2017) Management and Family Burdens Endorsed by Parents of Youth <7 Years Old With Type 1 Diabetes. J Diabetes Sci Technol 11:980-987
Thelin, Martin A; Kissler, Stephan; Vigneault, Frederic et al. (2017) In Vivo Enrichment of Diabetogenic T Cells. Diabetes 66:2220-2229
Lindsay, Robert S; Loeken, Mary R (2017) Metformin use in pregnancy: promises and uncertainties. Diabetologia 60:1612-1619
Mehta, Sanjeev N; Andersen, Henrik Ullits; Abrahamson, Martin J et al. (2017) Changes in HbA1c and Weight Following Transition to Continuous Subcutaneous Insulin Infusion Therapy in Adults With Type 1 Diabetes. J Diabetes Sci Technol 11:83-86
Chadwick, Jennifer Q; Van Buren, Dorothy J; Morales, Elisa et al. (2017) Structure to utilize interventionists' implementation experiences of a family-based behavioral weight management program to enhance the dissemination of the standardized intervention: The TODAY study. Clin Trials 14:406-412
Salastekar, Ninad; Desai, Tanvi; Hauser, Thomas et al. (2017) Salsalate improves glycaemia in overweight persons with diabetes risk factors of stable statin-treated cardiovascular disease: A 30-month randomized placebo-controlled trial. Diabetes Obes Metab 19:1458-1462
Hou, Yanyan; Kitaguchi, Tetsuya; Kriszt, Rókus et al. (2017) Ca2+-associated triphasic pH changes in mitochondria during brown adipocyte activation. Mol Metab 6:797-808
Forlenza, Gregory P; Argento, Nicholas B; Laffel, Lori M (2017) Practical Considerations on the Use of Continuous Glucose Monitoring in Pediatrics and Older Adults and Nonadjunctive Use. Diabetes Technol Ther 19:S13-S20
Simão, Fabrício; Ustunkaya, Tuna; Clermont, Allen C et al. (2017) Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke. Blood 129:2280-2290

Showing the most recent 10 out of 1033 publications